Diatranz Otsuka Limited (DOL) develops cellular therapies through xenotransplantation to improve the lives of people with serious diseases, including type 1 diabetes, and provides testing and consultation services for xenotransplantation programs.

Diatranz Otsuka Limited

Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.

Metric
Company Name	Diatranz Otsuka Limited	Otsuka Holdings Co., Ltd.
Symbol		4.58K
MSH ID	COM:DOLGLOBAL	COM:OTSUKA
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Drug Manufacturers - General
Country	NZ	JP
Stage
Employee Count		34.39K
Website	dolglobal.com	otsuka.com
LinkedIn
Founders

Metric
Market Cap		26.07B
Enterprise Value
Monthly Web Traffic		46.07K
Web Traffic Growth		1.45
Valuation
Raised Capital

Metric
Revenue		13.46B
Revenue (LTM)
Revenue (NTM)
Gross Profit		9.39B
EBITDA		2.60B
Operating Income		1.95B
Net Income		811.10M
EPS		1.49
Diluted EPS		1.49
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.71
Operating Profit Margin		0.15
EBITDA Margin		0.19
Net Profit Margin		0.07
Return on Equity		0.06
Return on Assets		0.04
Return on Capital Employed		0.11

DOLG

COM:DOLGLOBAL

Diatranz Otsuka Limited

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		16.87
P/B Ratio		1.25
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		2.26
EV Multiple		11.34

Metric
Days Sales Outstanding		94.09
Days Payables Outstanding		115.26
Days Inventory Outstanding		169.37
Operating Cycle		259.01
Cash Conversion Cycle		136.71
Asset Turnover		0.61

Metric
Operating Cash Flow		1.89B
Free Cash Flow		1.12B
Cash Flow to Debt		1.80
Operating Cash Flow/Sales		0.14
Free Cash Flow Yield		0.04

Metric
Cash & Equivalents		3.42B
Accounts Receivable		-212.10M
Inventory		1.66B
Goodwill		2.53B
Debt to Capitalization		0.07
Debt to Assets		0.05
Current Ratio		2.14
Quick Ratio		1.66

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.15
SG&A to Revenue		0.40